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ContractilityThe lymphatic systemplays critical roles in tissue fluid homeostasis and immunity and has been implicated in the
development of many different pathologies, ranging from lymphedema, the spread of cancer to chronic inflam-
mation. In this review, we first summarize the state-of-the-art of lymphatic imaging in the clinic and the advan-
tages and disadvantages of these existing techniques. We then detail recent progress on imaging technology,
including advancements in tracer design and injection methods, that have allowed visualization of lymphatic
vessels with excellent spatial and temporal resolution in preclinical models. Finally, we describe the different ap-
proaches to quantifying lymphatic function that are being developed and discuss some emerging topics for lym-
phatic imaging in the clinic. Continued advancements in lymphatic imaging technology will be critical for the
optimization of diagnostic methods for lymphatic disorders and the evaluation of novel therapies targeting the
lymphatic system.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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After the blood circulation, the lymphatic system is the second vas-
cular system in mammalian species. It fulfils vital functions such as
the maintenance of tissue fluid homeostasis, the initiation of immune
responses via the drainage of antigens and cells and the uptake of die-
tary lipids in the intestine. Present in most organs of the body, with
the notable exceptions of the brain and bone marrow, the lymphatic
system is composed of blind-ended lymphatic capillaries responsible
for the uptake of interstitial fluid and proteins and downstream
collecting lymphatic vessels that actively transport lymph fluid through
a series of lymph nodes to the blood circulation [1].
Imaging techniques for visualization of the lymphatic systemare less
well developed than those for imaging of blood vessels for two major
reasons. First, the lymphatic system is more difficult to “make visible”.
It is normally not apparent to the naked eye even during surgery and
its organization as a one-way transport network means that the entire
system cannot be easily visualized with a simple injection. Thus, imag-
ing of lymphatic system is usually performed after interstitial injection
(e.g. intradermal, subcutaneous or intramuscular) of tracers, the design
of which must take into account several factors to enable efficient up-
take by the lymphatic vessels of that specific tissue [2–4]. Second, the
importance of the lymphatic system in health and disease has been his-
torically underappreciated. Lymphatic vessels were commonly rele-
gated in the past as simple waste conduits responsible for the uptake
of only minor amounts of excess fluid produced within tissues; how-
ever, an improved knowledge of basic anatomy and physiology and in
our understanding of several diseases has indicated the critical role
that this system plays within our body [1,5,6]. Thus, for an increasing
number of clinical indications there has emerged a clear need for im-
proved imaging technology to visualize the lymphatic systemand quan-
tify its function in both patients and in preclinical models of disease.
In this review, we first summarize the established state-of-the art of
lymphatic imaging used in clinics. We then outline the most recent de-
velopments in the field of pre-clinical imaging, including the design of
novel tracers, methods of tracer delivery and new imaging modalities.
Next, we focus on preclinical and clinical imaging protocols for the
quantitative assessment of the lymphatic function. Finally, we highlight
promising novel lymphatic imaging techniques that are currently being
translated into the clinic.2. State-of-the-art of clinical imaging
Clinical imaging can deliver a variety of relevant information about
the morphology and function of the lymphatic vessels and lymph
nodes. Therefore, visualization of these lymphatic structures in different
parts of the body has been utilized to identify and stage numerous con-
ditions, such as lymphedema, cancer, chronic inflammation, chylous as-
cites and many others [2]. Moreover, imaging of the lymphatic system
can be used pre- or intra-operatively in surgical procedures where lym-
phatics are involved, for example sentinel lymph node (SLN) mapping
and metastatic staging, lymphovenous anastomosis (LVA), lymph
node transfer, tumor resection or transplantation. In the initial section
of this review wewill summarize the established clinical lymphatic im-
aging techniques and discuss their advantages and limitations Table 1.Please cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
10.1016/j.addr.2020.08.0132.1. X-ray lymphography
X-ray lymphography is the most conventional technique of lym-
phatic imaging dating back to the 1960s. In this method, a blue dye
(methylene blue) is first injected intradermally into the interdigital
space of the foot (transpedal lymphography) or hand, which allows
for localization of the lymphatic structures with the naked eye
(Fig. 1A). Alternatively, a lymph node can bemade visible using another
technique, for example through ultrasound (transnodal lymphograpy).
After that, the lymphatic structure (lymph vessel or lymph node) is can-
nulated with an iodinated, oil-soluble X-ray contrast agent, Lipidol,
followed by X-ray imaging (fluoroscopy, radiography or computed to-
mography) [7,8].
The advantage of X-ray lymphography is efficient penetration of the
X-raywaves into tissues,which allows for visualization of the deep lym-
phatic structures, such as thoracic duct and iatrogenic or idiopathic
leakage at different locations, such as chylous ascites, chylothorax,
chyluria or lymphocele [9–12]. In fact, although in some patients lym-
phography may itself have a therapeutic effect [12], it is often followed
by a direct surgical intervention to embolize the site of the leakage [11].
However, this two-step lymphography technique requires significant
time and training of the operator, and constitutes a burden for the pa-
tient, since for some procedures (e.g. for intranodal or direct thoracic
duct injections) the patient needs to be anesthetized and/or sedated.
Therefore, this imaging technique has been predominantly replaced
by other, less invasivemethods and is currently rarely used in clinics ex-
cept for imaging of the central lymphatics in certain indications.2.2. Scintigraphic methods
Lymphoscintigraphy is considered as the “gold standard” in clinical
lymphatic imaging. Most commonly, it is applied for diagnosis and stag-
ing of lymphedema and for SLN mapping. Approved technetium-99m-
labeled (Tc99m) lymphatic-specific tracers, varying in terms of size,
are used clinically. Typically, these are 99mTc-nanocolloidal (5–80 nm
diameter) human serum albumin [13,14] in Europe, 99mTc-sulphur col-
loid (filtered to a diameter below 100–200 nm) in the US and
99mTc-antimonium-trisulfide (5–30 nm) in Canada and Australia.
Other conjugates have also been used in clinical studies, such as
99mTc-phytate particles (10–20 nm) [15,16] or 99mTc-immunoglobulin
(around 10 nm) [17], 99mTc-dextran [18] or targeted tracers, such as
99mTc-tilmanocept [19–22] or 99mTc-rituximab [23,24].
For functional imaging of the lymphatic system, tracers of small size
are preferred to assure a rapid uptake from the injection site into the
lymphatic vessels [25]. A general protocol for assessing lymphatic func-
tion with lymphoscintigraphy involves interstitial (intradermal or sub-
cutaneous) injection of a radioactively labeled tracer in the interdigital
space of both healthy and lymphedemous hands or feet and static or dy-
namic imaging of the limbs, or occasionally the whole body, with a
gamma camera (posterior or anterior) to obtain an image of the lym-
phatic structures (Fig. 1B). Although the acquired images are typically
low resolution, their qualitative analysis provides descriptive informa-
tion about the symmetry of the tracer uptake in the lymphatics and
lymph nodes of the healthy and lymphedemous limb as well as pres-
ence of dermal backflow [16,26]. On the other hand, quantitative orlogy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
Table 1
State-of-the art clinical imaging of the lymphatic vasculature.





Lipidol Visualization of the central
lymphatic system
Deep penetration of the
X-ray waves into the tissues
Invasiveness (need for cannulation
of lymphatic vessels or intranodal
injection)





lymphatic function, imaging of
collecting lymphatic vessels,
visualization of dermal backflow,
SLN mapping
Deep penetration of gamma
waves, high sensitivity
Exposure to ionizing radiation,
poor spatial and temporal
resolution, planar image, lack of
standardization




SLN mapping, assessment of the
status of the lymphatic vessels
Tomographic
reconstruction to create a
3D image displaying the
localization of the
radioactive signal in
relation to other tissues
Exposure to ionizing radiation,
poor spatial and temporal
resolution, high costs
No limit 1–2 cm for
SPECT / ~50–
200 μm for CT
NIR lymphography ICG Quantitative assessment of
lymphatic function, imaging of
collecting lymphatic vessels,
visualization of dermal backflow
pattern, SLN mapping
Lack of exposure to ionizing
radiation, better spatial and
temporal resolution than
scintigraphy, low costs
Limited depth of imaging, lack of
appropriate clinically-approved
tracers for quantitative imaging












lymphatic vessel status, SLN
mapping, imaging of central
lymphatics
Lack of exposure to ionizing
radiation, high imaging
depth limit, 3D volumetric
images of the lymphatic
vessels can be obtained
Low lymphatic specificity of
clinically-approved tracers (higher
specificity can be obtained during
intranodal injection), venous
signal enhancement, high costs
No limit 0.5–2 mm
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measuring the disappearance of the tracer at the injection site after in-
terstitial administration [27], the kinetics of proximal lymph node up-
take [13] or a quantification of the asymmetry of the tracer uptake in
the limbs have been published [28]. It is important to note that in quan-
titative studies using lymphoscintigraphy the results need to be
corrected for the radioactive decay of the tracer itself.
Lymphoscintigraphy is alsowidely used for SLNmapping after inter-
stitial (e.g. intradermal, intratumoral or interareolar) injection of radio-
active tracers in several types of cancer [20,29]. After administration,
lymphoscintigraphic imaging is performed to localize the SLNs using
gamma cameras or intraoperatively using a portable gamma probe
that gives an acoustic signal upon detection of radioactivity. Newer por-
table gamma-cameras are being developed that are combined with op-
tical imaging to provide anatomical location of the SLNusing blue dye or
indocyanine green to provide a visual discrimination of the boundary to
finely guide surgical dissection [29–31]. An ideal tracer for SLNmapping
should exhibit rapid clearance from the injection site, rapid accumula-
tion and high retention in the SLN as well as low accumulation in the
downstream lymph nodes [25]. In the US, 99mTc-sulphur nanocolloid
is typically used for this purpose; however, due to its large size it is
slowly cleared from the injection site [32]. To overcome these issues,
targeted approaches have been developed. 99mTc-tilmanocept
(Lymphoseek, Navidea) is an FDA-approved lymphoscintographic
agent composed of 99m-Tc bound DTPA-mannosyl dextran, a macro-
molecule of size around 7 nm and 99mTc-rituximab, containing
99mTc coupled to a monoclonal antibody. Both tilmanocept and rituxi-
mab target cells residing in the lymph nodes: the former acts as a ligand
for the CD206 receptor on macrophages and dendritic cells and the lat-
ter for CD20 on the surface of B-lymphocytes, thus limiting the migra-
tion of the tracers into downstream lymph nodes [20,22].
Classical lymphoscintigraphy delivers only planar images and fails to
provide information about the accurate anatomical location of the lym-
phatic abnormalities or lymph nodes within the tissue. To address this
shortcoming, SPECT/CT imaging can be performed [33] where scinti-
graphic imaging with a specialized gamma camera is combined with
X-ray tomography. In particular, during the measurements, the 2D im-
ages are recorded by detectors placed at different angles, followed byPlease cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
10.1016/j.addr.2020.08.013a tomographic computer-assisted reconstruction to create a 3D image
displaying the localization of the radioactive signal in relation to other
tissues. Typically, SPECT/CT is used for precise, pre-operative SLN map-
ping inmultiple types of cancers to assist surgical planning [34–38]. Like
in classical lymphoscintigraphy, 99m-Tc-based probes are used in clini-
cal SPECT/CT imaging.
Currently, the technical aspects of protocols for scintigraphic
methods for staging and diagnosis of lymphatic insufficiencies and
SLN mapping vary among different medical centers worldwide in
terms of use of the tracer type, the injection route, the application of
stress activity to stimulate lymphatic uptake (e.g. applying temperature,
limb exercise) and the data analysis methods. This is amajor obstacle to
compare the findings across different studies [26,29]. Other limitations
of lymphoscintigraphy are related to its poor spatial and temporal
resolution as well as the need to use large, stationary and expensive in-
strumentation. The costs of production and disposal and the short radio-
active half-life of such tracers are also of high concern. These issues are
likely to hamper any major breakthroughs in the lymphoscintigraphy
field in the coming years [26].
2.3. Fluorescence imaging
Fluorescencemicrolymphography is a useful “office” test to visualize
the initial capillary lymphatic network localized in the dermis of the
skin. In this technique, which was originally developed in the early
1980s, FITC-dextran (150 kDa) is injected intradermally [39]. The fluo-
rescent tracer spread into the initial lymphatics is visualized with a mi-
croscope and is measured as the maximum distance from the outer
border of the dye deposit. More extensive spread of the tracer suggests
lack of drainage into the deeper lymphatic collecting vessels implying
their impairment. A cut-off of 12 mm spread has been shown to distin-
guish between healthy and lymphedema legs in patients with high sen-
sitivity and specificity [40–42]. However, this technique has been
scarcely adopted in the lymphology field, since FITC-dextran, although
well-tolerated in patients, is not officially approved for human use.
Near-infrared (NIR) lymphography is a relatively new technique
that has been first used in humans around 15 years ago [43–46]. In
NIR lymphography, the clinically-approved dye indocyanine greenlogy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
Fig. 1. State-of-the-art clinical imaging of the lymphatic system with tracer-based techniques. (A) X-ray lymphography. Radiographic image during axillary lymph node mapping with
Lipidol. In the left image, three larger afferent lymphatic collectors of the upper extremity are shown. Collectors (CC) are directed to larger, laterally-localized axillary lymph node (L).
Reproduced with permission [8]. (B) Lymphoscintigraphy. Lymphoscintigrams of the legs after subcutaneous injection of radioactive tracers in the feet (foot depots marked with the
arrows). Left image shows minimal lymphatic uptake in legs of patient with primary unilateral lymphedema. Right image shows the lymphatic routes and inguinal lymph nodes
imaged in normal control individual. Reproduced with permission [42]. (C) NIR lymphography. Dermal backflow patterns that correlate to severity of lymphedema and lymphatic
dysfunction in comparison to normal linear flow pattern (left). In extreme cases of no flow, the tracers may not extend beyond the injection site. Reprinted with permission [55]. (D)
Dynamic MR lymphography with Gd-based tracer in the upper arm with lymphedema. Progressive enhancement of the lymphatic channels over time. Irregular radiating lymphatic
channels are seen extending from the lateral forearm towards the medial left elbow in a characteristic irregular, beaded pattern (arrowheads). Reprinted with permission [66].
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interest (ROI) is imaged using a coupled-charged detector (CCD) cam-
era. ICG was originally FDA approved in 1959 for use in hepatic clear-
ance assessments and was later adapted for use in measurements of
cardiac output and ophthalmologic angiography. ICG has been widely
reported to bind serum albumin in vivo, however, studies have shown
that it binds even more strongly to HDL and LDL lipoproteins [47]. In
pioneering studies, the feasibility of visualizing abnormal lymphatic ar-
chitecture and lymph flow velocities in patients with secondary arm
lymphedema using this technique was shown [44,45]. Owing to high
light penetration and low scattering of light in the NIR range, this tech-
nique is capable of visualizing lymphatic structures up to 2 cm below
the skin using an ICG dose in the microgram range. Owing to improved
spatial and temporal resolution in comparison to lymphoscintigraphy,
NIR lymphography opens a variety of opportunities for precise delinea-
tion of lymphatic architecture and quantitative assessment of function
such as measurements of collecting vessels contractility [44,48–51].
For example, while with radioactive lymphoscintigraphy dermal back-
flow can be evaluated only in terms of presence or absence, NIRPlease cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
10.1016/j.addr.2020.08.013lymphography allows for observation of distinct dermal backflow pat-
terns (splash, stardust and diffuse) that are correlated to the severity
of lymphatic dysfunction and clinical symptoms (Fig. 1C) [52–55].
NIR lymphography has also been clinically useful in evaluating the
lymphaticflow in transplants (i.e. hand transplants, freeflap transplants
or vascularized lymph node transfer) [56,57], for identification of lym-
phatic vessels prior to LVA surgery [58,59] and during SLN mapping in
cancer patients [60]. Although for the latter application ICG is not ideal
due to its low molecular weight, resulting in its poor retention in the
SLN and leakage into the surgical field, it has been shown to be clinically
useful to detect SLNs inmany types of cancer (breast cancer, gynecolog-
ical cancers, melanoma, head and neck cancer) often in combination
with modern intraoperative imaging equipment [61–65]. An advantage
of using ICG in SLNmapping is the possibility of real-time tracking of the
lymph flow from the injection site to the SLN [61].
Despite the widespread use of ICG in the field of lymphatic imaging,
this indication, including all injection routes other than intravenous, re-
mains off-label. Moreover, the undesirable physicochemical properties
of ICG, such as poor stability, self-quenching and low quantum yield,logy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
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[67]. Thus, there is a clear need for clinically approved tracers for this
imaging modality that are optimized for the lymphatic system.
2.4. Magnetic resonance imaging
Magnetic resonance lymphography (MRL) imaging in the extremi-
ties is performed after interstitial injection of a T1-weighted Gd-based
contrast agent (typically Gd-DTPA or Gd-DOTA) that creates a desirable
positive enhancement signal. Owing to the high imaging depth of MRI,
3D volumetric images of the lymphatic vasculature can be obtained. In
particular, the location (including the depth) of dilated, tortuous lym-
phatics as well as the location and extent of dermal backflow can be
identified. The vessels can be visualized in relation to other anatomical
structures and/or pathological changes resulting from lymphedema
(i.e.fibrotic and adipose tissue accumulation or subcutis thickening) ob-
tained from 3D T2-weighted pre-tracer imaging [66,68]. In addition to
staging of lymphedema, MRL is especially useful in pre-operative imag-
ing prior to LVA surgery, in contrast to NIR lymphography, as its large
field of view allows for imaging of the whole extremity and for spatial
localization of the lymphatic and blood vessels within the healthy and
pathological structures,which facilitates the choice of theproper vessels
for the anastomosis [69–71].
Due to the low molecular weight of clinically utilized Gd-based
tracers (<1 kDa), after interstitial injection the contrast agent is
absorbed not only by the lymphatics but also by the blood vascular sys-
tem, which lowers the specificity of this imaging technique [72]. Lym-
phatic vessels may be distinguished from the blood vessels based on
their anatomical structure but they are sometimes not easy to delineate.
Another approach is to acquire a series of dynamic images and to distin-
guish lymphatic vessels as the vessels in which the tracer signal in-
creases and then slowly decays and blood vessels as those where the
signal enhancement decreases over time (Fig. 1D) [66,73]. As these
data are still often difficult to interpret, a second MRI imaging step
after intravenous injection of the same contrast agent (“delayed MR
lymphogram”) can be performed in order to distinguish the lymphatic
and blood vasculature [68].
Dynamic MRL allows for imaging of the central lymphatic system
(i.e. thoracic duct and cisterna chyli) or hepatic lymphatics and it is a
modern, emerging alternative to X-ray lymphography [74,75]. Similar
to this historical technique, the Gd-based tracer (Gd-DTPA or Gd-
DOTA) is usually injected intranodallywith the support of ultrasonogra-
phy to enable direct transport of the contrast agent to the central lym-
phatics followed by T1-weighted sequences [75,76]. Intranodal
injection of the tracers in combination with dynamic MRL seem to im-
prove the lymphatic specificity [76]. Moreover, recently central lym-
phatics were also successfully visualized in patients using a transpedal
MRL approach [77].
Non-contrast MRI lymphography sequences have been used for im-
aging of the central lymphatic system and lymphedema. The use of
heavily T2-weighted sequences for the imaging allows for highlighting
the signal from the stagnant fluid in the lymphatic vessels and in the tis-
sue, while depressing the signal from the tissue itself, thus depicting the
localization of the limb edema or the leak in the central lymphatics
[78–81]. The presence of the stagnated fluid within the fat tissue helps
to confirm the lymphatic origin of the swelling, as opposed to venous
origin [82]. In addition, as for MRL, the non-contrast MRI can visualize
the anatomical changes of the tissues affected by lymphedema [79].
However, non-contrast MRI is capable to visualize lymphatic vessels
onlywhen they becomedilated and filledwith stagnantfluid. Along this
line, the method is not suitable for dynamic flow analysis. For this pur-
pose, arterial spin labeling MRI, conventionally used to quantify blood
flow and tissue perfusion, can be applied to measure the lymphatic
flow velocity [83]. Another tracer-free MRI-based technique is chemical
exchange saturation transfer (CEST) MRI. In this method the contrast
originates from the protons associated with amide groups inPlease cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
10.1016/j.addr.2020.08.013endogenous proteins, whichmakes it sensitive to the protein-rich inter-
stitial environment. The accumulation the protein-rich interstitial fluid
is an indirect indication of lymphatic dysfunction, e.g., in lymphedema
[84,85]. The advantage of non-contrast MRI is its non-invasiveness
and reduced time of imaging compared to MRL resulting in lower
costs and a decreased risk of allergic reactions. However, the resolution
of this technique MRI remains poor. Moreover, further investigations in
larger groups of patients are necessary to validate its clinical utility.
The major advantage of MRI in contrast to X-ray lymphography is
that patients are not exposed to ionizing radiation. Lymphatic structures
can be visualized with a resolution higher than in lymphoscintigraphy
and NIR lymphography within the 3D volumetric structure of the sur-
rounding tissues when contrast agent is used. The major limitations of
MRI remain high costs of instrumentation and the advanced technical
skills required to operate the equipment and interpret the data. More-
over, the lack of appropriate clinically-approved lymphatic-specific
MRI tracers has hampered the utility of this imaging technique.
3. Technological advancements in preclinical lymphatic imaging
In vivo imaging of the lymphatic system in animal models has made
great strides in the past 15 years. Traditionally, in experimental studies,
lymphatics were visualized through tissue injections of ink or vital dyes,
such as Evans blue, that enabled the normally transparent vessels to be
visible during surgical manipulations or in thin skin preparations such
as the mouse ear [86–88]. However, advancements in tracer design
and imaging technology has enabled functional imaging of lymphatic
vessels in vivo at high temporal and spatial resolution, allowing an
array of techniques utilizing different imaging modalities to be devel-
oped.While some imaging approacheswere adapted from existing clin-
ical techniques, such as MRI and NIR fluorescence imaging, promising
newmodalities have also been introduced such as optoacoustic and op-
tical coherence tomography (OCT). In this section, we will highlight ad-
vancements in tracer design and delivery and describe by imaging
modality some of the recent innovations in preclinical lymphatic
imaging.
3.1. Tracer design and delivery
3.1.1. Size
Small-sized molecules (typically of size <5 nm diameter or below
10 kDa for proteins or polymers) diffuse rapidly in the interstitium
and can permeate to both blood and lymphatic capillaries [89,90].
Blood flow is approximately 100–500 times faster than lymph flow
within tissues, resulting in preferential clearance of small molecules
via blood capillaries. Due to the direction of the convective flow in the
interstitium from the blood to lymphatic vessels and discontinuous
button-like junctions between endothelial cells in lymphatic capillaries,
larger tracers are preferentially cleared via this route. For example, in
our recent study we encapsulated ICG in micelles of around 12 nm
consisting of Kolliphor HS15 (polyoxyl 15 hydroxystearate). After intra-
dermal injection of ICG-Kolliphor HS15 solution into the dorsal aspect of
the mouse foot, the tracer could be visualized only in the popliteal
collecting lymphatic vessels as opposed to free ICG, which was evident
also in veins draining the injection site [91]. It is generally agreed that
tracers within the size range of 10–100 nm are suitable for lymphatic
imaging and that their uptake rate from the injection site is size depen-
dent [92,93]. For example, Zbyszynski et al., investigated the clearance
of the sulfo-Cy5-labeled PEGylated functional upstreamdomain peptide
from the subcutaneous injection site in mice. The clearance half-life for
10–40 kDa conjugates was directly proportional to the molecular
weight of the PEG [92]. Similar results were obtained for FITC-labeled
dextrans in the size range of 5–54 nm. After intradermal injection, the
skin dye-polymer exposure over 72 h, as quantified by an AUC assess-
ment, increased with increasing molecular weight of dextran, with an
opposite effect found for lymph node exposure, indicating a retentionlogy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
6 A.K. Polomska, S.T. Proulx / Advanced Drug Delivery Reviews xxx (2020) xxxof the larger-sizedmolecules at the injection site and thus their reduced
transport to the lymph nodes [93]. Above 100 nm, the diffusion of the
entities in the interstitium and thus entry into the lymphatics is thought
to be limited by the size of the conduits in the extracellular matrix
(ECM) [25,94].
The exact choice of the tracer size depends on the application. For
example, tracers for lymphatic flow imaging should in principle be
smaller (5–10 nm) to allow for rapid lymphatic uptake and visualiza-
tion. On the other hand, the tracers for lymph node imaging should
have an intermediate size (10–100 nm) in order to accumulate in this
organ and thus provide strong signal [3,25,94–97]. For example, DSouza
et al., quantitatively visualized the lymphatic vessels and lymph nodes
after interstitial injection of two fluorescent tracers of different molecu-
lar weights, namely methylene blue (ca. 300 Da) and a fluorophore-
conjugated IgG (ca. 66.5 kDa) in the mouse hindlimb. Importantly, the
active lymphatic pumping was not affected by the molecular weight
of the tracer, as opposed to the passive diffusion affecting the uptake
by the lymphatics, which was reflected by the delayed time of reaching
the fluorescence peak in the afferent lymphatic vessel after injection of
the IgG and the higher signal compared tomethylene blue [98]. There is
no consensus in the literature concerning the “ideal” size of the tracer
for the SLN mapping. Many researchers claim it to be below 50 nm,
due to optimal balance between retention at the injection site and at
the lymph node [25]. However, Yang et al., investigated in mice a series
of self-assembled NIR fluorescent nanoparticles composed of amphi-
philic perylene diimide in the size range 50–200 nm for SLN imaging
using optoacoustic imaging. The optimal size of nanoparticles for SLN
imaging was found to be 100 nm due to 60 min interval in the arrival
time between investigated lymph nodes (popliteal and sciatic) after
local administration [96].
Many conventional tracers used currently in clinical lymphatic im-
aging, such as the MRI tracers Gd-DTPA or Gd-DOTA, isosulfan or ICG
dye, are of low molecular weight which limits their lymphatic specific-
ity. Therefore, a number of researchers use strategies like encapsulation
of tracer in nanoparticles such as liposomes [99,100], calciumphosphate
particles [101] or micelles [91], pre-complexation with polymers [102]
or proteins [103] or covalently attaching larger molecules (e.g. PEG)
[90,104–106]) to obtain lymphatic-specific tracers of larger size. For ex-
ample, Bisso et al., developed PEG-stabilized calcium phosphate nano-
particles (150 nm) loaded with MRI contrast agent, Gd-DTPA.
Intradermally injected nanoparticles exhibited slower uptake kinetics
in the popliteal lymph node and the MRI signal intensity exhibited
lower variability compared to freeGd-DTPA. A defined and reproducible
kinetic pattern would be an advantage in quantitative assessments of
lymphatic dysfunction [101].
3.1.2. Surface charge/properties
Negatively charged hyaluronic acid is one of the major components
of the ECM. Thus, negatively charged probes are preferred for in vivo im-
aging applications due to their lack of interactions within the ECM that
hinder their clearance from the interstitium and uptake by the lym-
phatic capillaries [107]. However, small particulate-based tracers with
only a slight negative charge have the tendency to aggregate upon injec-
tion in the interstitium. For example, negatively charged silica particles
with size 35–45 nm doped with Cy7 NIR fluorescent dye were investi-
gated in mice for lymph node mapping. When the negatively charged
carboxylic groups were exposed on the surface, the particles were
transported very slowly to the lymph node, presumably due to aggrega-
tion at the injection site. On the other hand, when the carboxylic acid
groups were masked with PEG and buried within the core of the parti-
cles, particles were transported rapidly to the lymph nodes, reaching
the peak fluorescence signal within minutes after injection [108]. Ag-
gregation could also be a reason for the lack of size-dependency of
skin retention and lymph node accumulation of small polystyrene par-
ticles injected intradermally in mice [93]. In another study, negatively
charged G4-G8 carboxy-terminal dendrimers were cleared from thePlease cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
10.1016/j.addr.2020.08.013injection site and then detected at the lymph node, while the same gen-
eration of amino-terminal dendrimers were stuck in the interstitium.
Interestingly, slightly negatively charged G4-G8 acetyl-terminal
dendrimers exhibited diffusion into the blood despite their larger mo-
lecular weight [89].
However, in some cases, positively charged species can also be effi-
ciently cleared from the injection site. For example, 100 nm positively
charged poly-arginine capsules accumulated to a higher extent in the
popliteal lymph node of mice after intradermal injection in comparison
to negatively charged anionic carboxymethyl-beta-glucane and chito-
san capsules of similar size. It is possible that certain positively charged
polymers, such as poly(arginine), may confer special properties to the
surface of the tracer that could alter their interactions with the endoge-
nous soluble proteins and small molecules, forming a “corona” on the
surface of the nanocarriers. This may alter their interactions with the
ECM and thus uptake by the lymphatics [109]. If cleared efficiently
from the injection site, positively charged tracers would be indeed ben-
eficial for lymph node imaging, as they tend to accumulate at this site
due to uptake by the immune cells. It needs to be investigated in more
detail how the protein corona influences the interactions and retention
within the interstitium and lymph node. Interestingly, potential specific
binding of the probe to interstitial proteins appears to have little influ-
ence on the retention of the probe at the injection site, unlike the effect
of probe size. Replacing thefibronectin-binding peptide (FUD) in a FUD-
sulfo-Cy5-PEG conjugate with its non-binding version (mFUD) had no
significant influence on the clearance half-life for any of the PEG conju-
gates [92].3.1.3. Tracer delivery
Lymphatic-specific tracers are usually delivered using conventional
injection techniques into the interstitium (e.g. through intradermal,
subcutaneous, intramuscular or intratumoral routes) from where they
reach the lymphatic vasculature. Among these delivery routes, intrader-
mal injection is preferred due to its accessibility and the high interstitial
pressure generated by the dense collagen matrix, driving the rapid up-
take of the injected tracer into the initial lymphatics [17]. However, in-
tradermal injection using conventional Mantoux technique requires
specialized training and may create discomfort and pain [110].
Microneedle-based delivery has been attracting a lot of attention
not only in the context of drug and vaccine delivery [111,112] but
also for diagnostic and monitoring applications [113]. Microneedles
allow for a pain-free and precise delivery of the tracer to a specific
depth in the skin dermis. For example, we embedded ICG in
400 μm-long solid polymeric microneedles composed of poly(N-
vinylpyrrolidone). After application on mouse skin, the polymer ma-
trix dissolved thus releasing the tracer. These needles allowed for
qualitative imaging of the leg lymphatic vessels as well as for quanti-
tative assessments of lymphatic clearance in mouse ears based on
disappearance of the tracer from the injection site [102]. However,
the low quantity of delivered ICG and poor mechanical stability of
the microneedles constitutes their major limitations. Therefore, in
our recent work, we used 600 μm-long solid hollow microneedle-
based devices, MicronJet600™ (Nanopass Ltd), to deliver micellar
ICG solutions into pig skin [91]. These CE-certified devices consist of
three hollow pyramidal-shaped silicon crystal microneedles embed-
ded on the plastic base and are compatible with standard syringes.
Thus, they can be easily implemented into clinical settings [114].
Kwon et al., have developed an interesting intradermal delivery
system, SOFUSA™, consisting of a hollow 350 μm-long silicon
microneedle array with nanotopographical polymer film on the sur-
face, attached to a syringe pump. Although the systemwas developed
for the delivery of immunotherapy to the lymph nodes, it is also
suited for imaging applications. Namely, the authors have shown
that the lymph nodes could be successfully visualized in vivo in rats
and in humans after delivery of ICG with SOFUSA [115].logy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
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3.2.1. MRI
MRI has been employed for over 20 years for preclinical lymphatic
imaging applications. Early workwas primarily focused on the develop-
ment of macromolecular contrast agents that would enable visualiza-
tion of lymph nodes, of interest for image-guided mapping of SLNs (as
reviewed inMisselwitz [116]). These studies have centered on formula-
tions of Gd-based contrast agents that could be administered into inter-
stitial tissue for subsequent lymphatic transport and visualization of
draining lymph nodes [117–120]. While some agents did show great
promise for this application, potential concerns regarding the toxicity
of Gd-based contrast agents have prevented macromolecular-based
MR contrast agents from reaching the clinic.
While the high costs and advanced technical knowledge necessary
to operate MRI have limited the application of this technique for pre-
clinical lymphatic studies, the developed Gd-based contrast agents
have found some utility for basic research. The group of Alana Ruddell
has performed a series of studies using dynamic MRI assessing the ef-
fects of melanoma tumor growth and metastasis on lymph flow in
mice [121–123]. The authors compared three different Gd contrast
agents for tumor-draining lymph node detection and found that a
75 nm lipid nanoparticle exhibited the best uptake into inguinal
lymph nodes in mice [123]. The authors speculated that the remodeling
of the lymph node that occurs in response to the tumor may improve
the barrier function of the lymph node to improve retention of nanopar-
ticles. Supporting this hypothesis, less nanoparticles were found in
downstream second-tier nodes of tumor-draining lymph nodes com-
pared to uninvolved lymph nodes. The mechanism of this improved re-
tention still remains to be elucidated but may have significance for the
delivery of immunotherapy to tumor-draining lymph nodes.
Müller et al., utilized AGuIX, sub-5 nm nanoparticles composed of a
polysiloxane core and gadolinium chelates, and 9.4 Tesla MRI for the in-
vestigation of lymphatic drainage in a rat hindlimb lymphedemamodel
[124]. In healthy animals, these methods allowed excellent anatomical
visualization of lymphatic vessels and lymph nodes with high signal-
to-noise ratios (Fig. 2A). After lymphadenectomy of the popliteal
lymph node, the imaging revealed lymphatic rerouting through collat-
eral lymphatic vessels that peaked at 6 weeks and gradually subsided
over time.
Recently, there has been a renewed interest in imaging the lym-
phatic drainage of cerebrospinal fluid (CSF), a process long-thought
to occur directly to veins [125,126]. Several groups have begun to
employMRI to visualize this process after injection of Gd-based contrast
agents into the CSF space in rats and mice [127–130]. Dynamic
contrast-enhanced MRI techniques have visualized the distribution of
the contrast agents within the CSF and mapped the outflow routes to
cranial-draining lymph nodes in the cervical region. We have also re-
cently utilized MRI with a 17 kDa dendritic Gd-based contrast agent,
Gadospin D, in conjunction with fluorescence imaging to characterize
the CSF outflow routes from the spine to the sacral and deep iliac
lymph nodes [131]. Alterations in the lymphatic drainage of CSF and,
by extension, the immunosurveillance of the CNS, have been implicated
in several conditions including aging and neurodegeneration, multiple
sclerosis and glioblastoma [132–135]. Advanced MRI quantifications of
the CSF clearance process to lymphatics are being developed and will
be critical for the assessment of novel drug formulations for these
conditions.
3.2.2. et PET
PET has limited utility for lymphatic vessel imaging in small animal
models due to issues of poor resolution, high equipment costs and the
need for radioisotopes. Nonetheless, because of its high sensitivity and
excellent depth penetration through the whole animal, it has been suc-
cessfully applied for detection of lymph nodes in rodents, as demon-
strated in the following studies.Please cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
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et al., to allow sensitive visualization of lymph nodes undergoing
lymphangiogenesis, an early stage biomarker for tumor metastasis in
several types of cancer [136]. Utilizing intravenous injections of anti-
bodies specific for a lymphatic vessel marker, LYVE-1, the authors
were able to demonstrate enrichment of the radioiodinated PET probe
in melanoma-draining lymph nodes in mice. Imaging of metastasis in
the draining lymph nodes using this probe was found to be more sensi-
tive compared to the [18F]fluorodeoxyglucose (18F-FDG) PET com-
monly utilized in the clinic.
Thorek and colleagues utilized PET in conjunction with CT and MRI
for 3Dvisualization of draining lymphnodes inmice [137,138]. In an ini-
tial study, the authors injected 18F-FDG intradermally in the tail and
were able to visualize the sacral and deep iliac lymph node groups en-
hancing with the tracer (Fig. 2B). Activity curves over timewere gener-
ated allowing quantification of the tracer uptake into the different
lymph nodes [137]. However, the rapid clearance into the blood of
this small molecular weight probe is a limitation. In a second study,
this group introduced a multi-modal nanoparticle, 89Zr-ferumoxytol,
of 17–35 nm in diameter that allowed PET/MRI detection of lymph
nodes after administration in the forepaw or to the prostate of mice
[138]. While concurrent anatomical visualization of lymph nodes with
MRI is a desirable feature, the negative contrast generated by this iron
oxide-based contrast agent is a drawback.
Another group has developed a tri-modal PET probe using 64Cu silica
nanoparticles that can be used for lymph node detection with fluores-
cence imaging using a NIR dye and MRI using Gd+3 chelation [139]. In
a tumormodel, the authors compared the detection of the SLN between
the three different imaging modalities over the course of several days.
This comparison revealed the low sensitivity of the MRI to detect the
probe as well as the loss of the PET signal due to the short radioactive
half-life of 64Cu. This group has also developed a smallmolecularweight
18F PET probe conjugatedwith Evans blue dye,which takes advantage of
the inherent property of this dye to bind albumin in the interstitial space
[140]. This approach is more favorable from a biosafety standpoint. As
Evans blue dye has both visible and fluorescence properties, the authors
propose that such a tracer may also be used during surgery.
3.2.3. Fluorescence imaging
The recent development of methods for preclinical imaging of the
lymphatic system has largely centered on fluorescence imaging due to
its cost-effectiveness, superior resolution, and lack of radiation expo-
sure. Pioneering studies from the group of Rakesh Jain adapted the fluo-
rescentmicrolymphangiography technique originally developed for use
in human skin for lymphatic imaging in themouse tail [39,141]. Imaging
in the tail with FITC-dextran was then extended to studies of lymph-
edema induced after a circumferential wound and to lymphatic vessels
near tumors using a murine sarcoma implanted under the tail skin
[142,143]. Dextran dyes were further utilized to image tumor-
associated lymphatic vessels using multiphoton microscopy of the tail
[144], within window chambers in the flank [145] and of the mouse
ear [146].
Fluorescent dextrans were also utilized to demonstrate altered lym-
phatic morphology in transgenic mouse models, including hyperplasia
of the lymphatic vessels in the tail and ear skin of K14-VEGF-C and -D
mice [147,148] and abnormal developing collecting lymphatic vessels
in Foxc2−/− mice [149]. However, the development of lymphatic-
specific fluorescent reporter mice has allowed for the visualization of
lymphatic morphology in a tracer-free manner. A number of these
mice expressing fluorescent proteins under lymphatic promoters such
as Prox1 and VEGFR-3 have now been generated [150–154] and have
gained widespread use in the lymphatic research community. Novel
high-resolution 3D imaging approaches to visualize the lymphatic ves-
sels in these reportermice embryos has shed new light on the beginning
stages of lymphatic development [155,156]. A related approach using
bioluminescent reporter mice expressing firefly luciferase under thelogy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
Fig. 2.Overview of preclinical lymphatic imagingmodalities. (A) MRI scan of rat hind limb before (left) and after (middle) intradermal injection of AGuIX nanoparticles of 3 nmdiameter.
Collecting lymphatic vessels (arrowheads) draining to and from the popliteal lymph node (arrow) can be visualized. Intravenous gadofosveset injection (right) was performed 2 h after
AGuIX application for simultaneous visualization of blood vessels. Reproduced with permission from [124] (B) Three-dimensional PET/CT rendering of lymphatic system draining the
mouse tail after intradermal administration of 18F-FDG (insert is without fused CT). Lymphatic vessels in the tail leading to sacral nodes (1), caudal (2) and mesenteric nodes (3) can
be clearly visualized. Reproduced from [137]. (C) NIR visualization of lymphatic vessels after intradermal injection of PEGylated fluorescent tracers in C57BL/6 albino mice. Images
acquired with a NIR stereomicroscope of the tail (upper left), ear skin (upper right), flank skin (lower left) and hind limb with popliteal lymph node (lower right) are shown.
Reproduced with permission from [90]. (D) Photoacoustic microscopic images of a mouse ear at 560 nm (left) and 595 nm (right) after intradermal injection of 3% Evans blue dye.
Blood vessels are visualized through hemoglobin detection at both wavelengths while dye-filled lymphatic vessels are more apparent at 595 nm. Reproduced from [184]. (E) Optical
coherence tomography technique for visualization of lymphatic vessels in the mouse dorsal skin. Through negative scattering, lymphatic vessels are apparent as empty spaces within
the tissue (b). Lymphatic valves are also apparent (white arrowheads). OCT allows visualization of more lymphatic vessels compared to traditional Evans blue lymphangiography
(c) Reproduced with permission from [189]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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lymphangiogenesis in inflammation and tumor models [157].
Fluorescence imaging in the visible wavelengths (400 to 700 nm) is
limited due to high absorption of photons by endogenous tissue constit-
uents. Additionally, significant tissue autofluorescence in this range also
increases the background signal that is obtained. To address these limi-
tations, many investigators have shifted to NIR wavelength (700 to
900 nm) imaging where photons of light can more easily penetrate tis-
sue, allowing detection of deeper structures such as collecting vessels or
lymph nodes located under the skin. An early focus of this work was
centered on the use of NIR quantum dots, which are extremely bright
nanoparticles containing a core of heavy metals, for SLN detectionPlease cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
10.1016/j.addr.2020.08.013[158]. They can be easily tuned to a wide variety of wavelengths, a fact
that was exploited in a study by Kobayashi et al., to simultaneously
map five lymph node basins in a single mouse [159]. Despite this
great promise, toxicity concerns have limited the potential of quantum
dots, with one study demonstrating particles remaining in reticular or-
gans of mice even two years after intravenous injection [160].
Similar to clinical NIR lymphography, studies using custom imaging
devices in both swine and murine models have demonstrated that
collecting lymphatic vessels can be visualized in a dynamic manner
after intradermal ICG injection [161–163]. Although it is inexpensive
and has an excellent safety profile, ICGhasmany drawbacks in its native
form for lymphatic imaging. It is a weak fluorescent dye with poorlogy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
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lymphatic specificity and the brightness of the dye are dependent on
protein binding in the interstitium, which may not always occur suffi-
ciently depending on the dose administered and the state of the tissue
[90,164]. Our group has formulated a more stable formulation of ICG
by encapsulating it in the lipid bilayer of pegylated liposomes of approx-
imately 60 nm diameter [100]. Upon intradermal injection, the in-
creased brightness of this formulation over native dye and the
specificity for the lymphatic system allowed detection of lymph nodes
up to 1 cm deep in mice with a commercially available whole animal
imaging system. ICG has also been encapsulated in micelles [91], em-
bedded in nanogels [165], complexed to polymers [102], lipid nanopar-
ticles [99] or pre-mixedwith albumin [166–168] for lymphatic imaging.
New fluorescent tracers for preclinical lymphatic imaging based on
conjugates of the bright NIR dye, IRDye, and PEG polymers have been
introduced [90,169]. We found that conjugates composed of > 10 kDa
PEG molecules were exclusively drained by the lymphatic vessels after
injection into skin. Unlike dextrans or quantum dots, uptake by phago-
cytes with subsequent retention in the draining lymph node was not
detectable [3]. These particles also appear to be biologically inert with
little adhesion to constituents of the extracellular matrix or lymphatic
endothelium. Weiler and Dixon have found that use of PEG-dye conju-
gates prevented the detrimental effects on lymphatic contractility and
expansion of the lymph node that occurs for many days after an injec-
tion of ICG into the rat tail [167]. In both solution and in vivo, PEG-dye
conjugates exhibit excellent stability with clearance in intact form
through the kidney from the blood circulation [90].
Microscopic systems have been customized for sensitive imaging in
the NIR spectrum. Adaptation of commercially available stereo or zoom
epifluorescence microscope setups with the addition of appropriate fil-
ters, light sources and NIR-sensitive cameras, has enabled noninvasive
in vivo image acquisition of lymphatic vessels with high spatial and
temporal resolution (Fig. 2C) [90,166]. These methods have been
employed to visualize alterations in lymphatic function and flow
rerouting in animal models of cancer and lymphedema [90,170–172].
The techniques have also gained utility to evaluate lymphatic function
in transgenic models of genes responsible for the growth and/or main-
tenance of lymphatic vessels [173,174]. Similarly, utilization of tracer in-
jections into lymphatic transgenic reporter mice enables a combined
functional and anatomical imaging approach that has allowed mapping
of lymphatic drainage from the skin, the peritoneal cavity and the cen-
tral nervous system [131,132,175,176]. The non-invasive nature of NIR
imaging and the favorable characteristics of the lymphatic-specific
tracers have stimulated the development of several quantitative mea-
sures of the lymphatic system in preclinical models, as outlined later
in this review.
3.2.4. Photoacoustic imaging
Photoacoustic imaging, also known as optoacoustic imaging, is a hy-
brid imaging technique that combines optical absorption and ultra-
sound detection. The tissue of interest is illuminated with a short
pulsed, non-ionizing light. After the light is absorbed by the tissue com-
ponents, heat is generated that leads to thermoelastic expansion and
thus ultrasonic emission. The generated ultrasound waves are mea-
sured with transducers to generate an image. Therefore, this technique
is often referred to as “light in, sound out” [177]. Since ultrasoundwaves
can be detected with high resolution, at greater depths and with less
scattering than optical imaging, this imaging modality has tremendous
promise for the imaging of lymphatic vessels and lymph nodes in both
animal models and humans. However, unlike blood vessels, which can
be detected with photoacoustic detectors based upon endogenous sig-
nals such as hemoglobin, lymphatic vessels still require exogenous
tracers for detection. Photoacoustic imaging is highly scaleable, with
very high spatial resolution, albeit at low depth penetration, using pho-
toacoustic microscopy or with a higher depth penetration up to several
cm but lower resolution using photoacoustic tomography [177–179].Please cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
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system focused on the detection of lymph nodes, mostly for SLN map-
ping applications [180,181]. For example, Erpelding et al., utilized intra-
dermal injections of methylene blue dye to visualize axillary lymph
nodes in rats. The authors were able to prove that signals within
lymph nodes that were located 2.5 cm below the imaging probe could
be detected by adding chicken breast samples on top of the rat skin sur-
face [182]. Further development of this technology allowed visualiza-
tion of collecting lymphatic vessels afferent to the axillary lymph node
of rats after injections of nanoparticles such as gold nanostars [183].
The potential of this technique for lymphangiography was pushed
further with a photoacoustic microscopy approach to image lymphatic
vessels in the tail and ear skin of mice after Evans blue dye injections
[184]. Using multispectral imaging, the authors were able to simulta-
neously visualize the blood vessels using the endogenous hemoglobin
signals (Fig. 2D). Inmultispectral imaging, a series of images is recorded
at different wavelengths. Based on the knowledge of absorption spectra
of the molecules of interest (e.g. ICG) and the background molecules,
their distribution can be determined using spectral unmixing algo-
rithms. However, the exact quantification of the absorber concentration
at depth requires correction due to the fact that the attenuation of the
light varies with the wavelength [185]. Another group utilized a com-
mercially available photoacoustic imaging system to visualize the
pumping of collecting lymphatic vessels at 3 to 5 mm deep in the hind
limb of mice [186]. The authors assessed the potential of several
different dyes, including Evans blue and ICG, for this assay and detected
contraction rates similar to those assessed by NIR imaging in isoflurane-
anesthetized mice [187,188].
3.2.5. Optical coherence tomography
Optical coherence tomography is a technique that allows label-free
3D reconstruction of the optical scattering within tissues. Lymphatic
vessels have been shown to be “visible” with this technique through
negative contrast from high-scattering surrounding tissue and can be
further differentiated from blood vessels due to the presence of few
intraluminal cells (Fig. 2E) [189–191]. The technique allows rapid volu-
metric scanning, enabling dynamic quantifications of collecting lym-
phatic function as outlined below. However, similar to other
fluorescence methods, the imaging is limited by depth, in this case to
structures less than 2 mm below the tissue surface. With a microscopic
OCT approach, lymphatic vessels have been renderedwithin the cornea
of mice that have been treated with sutures to induce inflammatory
lymphangiogenesis [192]. Conjunctival lymphatic vessels have been vi-
sualized ex vivo in porcine eyes by another group [193]. Further studies
are necessary to evaluate the potential of this technique for imaging of
ocular lymphatic vessels in the clinic.
4. Pre-clinical and clinical quantitative imaging assessments of
lymphatic function
The advancements that have been made in tracer design and imag-
ing technology detailed in the previous sections of this review have
enabled several different methods for quantifying the function of the
lymphatic system to be developed. These quantitative measures have
improved preclinical studies by allowing unbiased assessments of inter-
ventions aiming to stimulate or diminish lymphatic transport and serve
as emerging diagnostic markers for the clinic. We will first describe
methods that have focused on assessing the function of collecting lym-
phatic vessels and then discuss techniques that can measure lymphatic
transport from a tissue of interest.
4.1. Collecting lymphatic vessel contractility
The contractility of collecting lymphatic vessels is traditionally stud-
ied in preparations of isolated lymphatic vessels, dissected from such
species as sheep, rabbits or rats [194–196]. Thesemethodshave recentlylogy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
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genicmousemodels [197,198]. In these setups, parameters such as infu-
sion pressure and temperature can be easily controlled and modulated.
Thus, much has been learned from these studies regarding the physiol-
ogy of collecting lymphatic vessels and the factors that control their
contractility and valve function. However, the limitations due to the
ex vivo nature of these studies have led to a significant push to develop
in vivo imaging methods in which vessels can be studied under more
physiological conditions, as well as in preclinical models of human
disease.
The group of Timothy Padera has developed an intravitalmicroscopy
technique for the imaging of popliteal collecting lymphatic vessels after
FITC-dextran injection into the footpad ofmice [199]. Dynamic video ac-
quisition of the contractility of the lymphatic vessels in mice was possi-
ble for the first time, however, a surgical dissection of the skin
overlaying the vessels and a positioning of the mouse in an upright po-
sition were necessary in order to allow imaging on an inverted micro-
scope. Nonetheless, this method has shed light on the effects of
different cellular sources of nitric oxide on lymphatic contractility.
Early reports describing noninvasive NIRF techniques to visualize
collecting lymphatic vessels have reported quantifications of theFig. 3. Imagingmethods allowing quantification of collecting lymphatic vessel function. (A) Fluo
Prox1-GFP transgenic reporter mouse flank after infusion of PEGylated tracer into the inguinal
stages of the contraction cycle. (B) Example semi-automated analysis plot with peak detection (
vessel contraction frequency and amplitude from NIR imaging. Reproduced from [201]. (C) D
lymphatic vessel and valve in the mouse hind limb at different stages of the contraction
measurement in the upper arm using NIR lymphography in humans. Lymphatic pumping pre
cuff (arrow). Reproduced with permission from [50]. (For interpretation of the references to c
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[90,162,187]. It was unclear exactly what these measurements repre-
sented in the context of the contractility of the collecting vessels or
the overall efficiency of lymph transport. It was also evident that mea-
surements of frequency alone would only tell one part of the story, as
contraction strength or amplitude was not assessed. Indeed, a recent
study has shown thatmeasurements of frequency had no direct correla-
tionwith estimates of overall lymph transport [200]. Thewide variety of
frequencies of these events reported in the literature was another
source of confusion [188].
Using an exteriorized preparation of the flank collecting lymphatic
vessel in Prox1-GFP mice, we have shown that measurements of vessel
diameter are directly correlated with the intensity of fluorescence that
is measured using a region of interest covering the vessel (Fig. 3A)
[201]. This has since been confirmed by another study in rats from the
group of Brandon Dixon [200]. Thus, these studies have demonstrated
that measurements of fluorescence signal intensity dynamics, as may
be recorded in a noninvasive fashion, can provide information on con-
traction strength aswell as frequency. Our group and others have devel-
oped analysis algorithms for the evaluation of contraction frequency
and amplitude based on NIR fluorescence imaging (Fig. 3B) that haverescencemicroscopy visualization of a contractile collecting lymphatic vessel and valve in a
lymph node. Images of endogenous GFP signal (upper) and NIR tracer (below) at different
red circles) andmean signal intensity (blue line) for quantification of collecting lymphatic
oppler OCT cross-sectional images perpendicular to (left) and along (right) a collecting
cycle. Reproduced with permission from [206] (D) Illustration of pumping pressure
ssure is defined as the cuff pressure when the ICG dye exceeded the upper border of the
olour in this figure legend, the reader is referred to the web version of this article.)
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collecting lymphatic vessel function [200–202]. These in vivo analysis
techniques can thus complement the findings from ex vivo studies of
collecting lymphatics.
Direct measurements of the pumping frequency, amplitude and
pumping velocity using NIR fluorescence imaging are also possible in
humans [44,48–51]. According to recent publications from a clinical
group in Denmark, these parameters have low intra-individual and
intra-observer variability in legs and arms that suggest that they may
be used to evaluate the function of the lymphatic vessels in health and
disease [50,51].
We have found that one source of disparity in the observed frequen-
cies fromdifferent research groupswere the effects of different anesthe-
sia regimens on contractility [188]. For example, isoflurane has been
shown to decrease lymphatic contraction rates in a dose dependent
fashion [203]. Other factors such as animal positioning and injection
volume also appear to play significant roles [204]. Indeed, the require-
ment for an injected tracer to perfuse the lymphatic vessel is a severe
limitation of these quantitative in vivo methods, as there is known to
be a direct effect of intraluminal pressure on collecting lymphatic vessel
contractility [197]. This can be easily observed after an external com-
pression (i.e. massage) of the injection site, which loads more tracer
into the downstream lymphatic vessels and has immediate effects on
the contractility rates [90].
To address this limitation, Blatter and colleagues have explored the
capability of a tracer-free Doppler OCT (DOCT) technique for the assess-
ment of lymphatic flow [205,206]. DOCT systems are able to measure
the motion of scattering particles in the tissue. Using B-mode Doppler
methods, acquisition rates of 50 Hz can be achieved. By monitoring
the movement of particles within the lymphatic vessels or the motion
of the surrounding tissue the authors are able to estimate parameters
of lymphatic contractility. Visualization of the lymphatic valve function
is also possible with these techniques (Fig. 3C). However, one existing
limitation with this technique is that the skin above the collecting lym-
phatic vessels needs to be surgically dissected due to its high amount of
optical scattering.
4.2. Lymphatic pumping pressure
A clever quantitative approach for measuring lymphatic function
estimates the pumping pressure of the collecting lymphatic vessels.
This technique was first developed in the clinic by combining
lymphoscintigraphic imaging with an inflatable pressure cuff [207].
Pumping pressure has been proposed to be a relevant parameter that
correlates with the intrinsic active contractile function of the lymphatic
collectors and extrinsic forces such as muscular activity that drive
lymph propulsion against an increasing hydrostatic pressure gradient.
In this method, an inflatable congestion pressure cuff is applied on the
limb and an interstitial lymphatic tracer is injected distal to the cuff.
While the pressure of the cuff is gradually reduced, thewhole limb is dy-
namically imaged until the tracer flow is restored. The effective pumping
pressure of the lymphatic vessels is the pressure reading at which the
vessels are capable of transporting the tracer through the cuff. Using
this technique in combination with lymphoscintigraphy, it was demon-
strated that womenwho developed lymphedema after breast-cancer re-
lated lymphadenectomy2 years post-surgery had a higher pre-operative
pumping pressure compared to those that did not develop the disease
[14]. This surprising result was determined from a relatively small
group of patients and requires further confirmation. Pumping pressure
has also been determined in human upper and lower limbs using the
cuff method combined with ICG imaging (Fig. 3D) [50,51,208–210].
Nelson and colleagues have established these techniques for the es-
timation of lymphatic pumping pressure in collecting lymphatic vessels
of the rat [172]. The systemwas validatedwith the application of a nitric
oxide donor cream that has been shown to inhibit lymphatic contractil-
ity. In a further study, the technique was used to demonstrate that thePlease cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
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the location of the pressure cuff. When the cuff was placed near the
base of the tail the pressure generated was significantly higher than
when the cuff was locatedmore distally. The authors attributed this dif-
ference to the number of lymphangions available to generate the con-
tractile forces [211]. The technique was also recently applied by the
same group to assess the functionality of collecting lymphatic vessels
in a lymphatic injury model in the hind limbs of sheep [172].
4.3. Lymphatic clearance
Perhaps the simplest method to quantify lymphatic function is to
monitor the disappearance (clearance) of injected tracers at the site of
injection. A clinical scintigraphic method that can track lymphatic re-
moval of an interstitial depot of radiolabeled tracer has been established
for assessment of the lymphatic function in patients with lymphedema
[27]. One obvious limitation of a scintigraphic-based clearance method
is the need to take into consideration the radioactive half-life of the
tracer. Usingfluorescence imaging, preclinical techniques formeasuring
lymphatic clearance have been established using human albumin la-
beled with fluorescent dye [212], PEGylated NIR dyes [213] or ICG
non-covalently bound to non-toxic polymer [102] or encapsulated in
micelles [91]. In each case, lymphatic function can be modeled as a
one-phase exponential decay over time (Fig. 4A). Advantages of this
technique include the need for only minute amounts of tracer, the abil-
ity to measure rapidly and the requirement for relatively few measure-
ments to fit to the decay model. This means that measurements can be
performed in animals that are only shortly anesthetized ormanually re-
strained, thus allowing the clearance of the tracer to occur under normal
physiological conditions between timepoints. Using this technique, we
have compared the effect of aging on lymphatic clearance from the
mouse ear skin and have found a significant decrease in the clearance
rate in aged versus young animals [213]. Another group has shown
that clearance can be monitored with NIR imaging from the knee joints
in rats after intraarticular injection of PEGylated tracers [214]. Lym-
phatic clearance assessments have also been recently established
using photoacoustic imaging. Yücel et al., have developed a technique
in which the clearance of a NIR quencher dye, QC-1, bound to bovine
serum albumin was tracked after injection into the anterior chamber
of the eye in mice [215].
4.4. Tracer transport to lymph nodes and/or blood
In the past, in vivomeasurements of lymph flow in animalmodels
from a specific anatomical site required surgical procedures such as
cannulation of collecting lymph vessels for tracer recovery. The com-
plicated anatomy of the lymphatic system, with multiple collecting
vessels draining each organ and inconsistent routing of these vessels
between individual subjects was a severe limitation of such studies.
In rodents, suchmethods are technically demanding due to the small
size of the collectors and have thus been restricted to larger lym-
phatic trunks, such as the thoracic duct [216]. Imaging approaches
have thus largely replaced these methods by using non-invasive
measures of tracer flow through draining lymph nodes or to the sys-
temic blood circulation.
Several imagingmodalities have the sensitivity and resolution capa-
ble of detecting signal intensity dynamics of lymphatic tracers within
lymph nodes. As mentioned previously, such assessments have been
made with PET/CT, MRI and fluorescence imaging techniques
[100,131,137]. Depending on the tracer, lymph node signals will either
increase steadily over time (as ameasure of tracer retention) or will ini-
tially increase and then decrease (as a measure of lymph flow through
the node) [3]. The first approach would be more desirable for the opti-
mization of drug delivery or diagnostic techniques targeting the
lymph node, while the second approach is more suited for assessment
of lymphatic function.logy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
Fig. 4.NIRfluorescence imagingmethods allowing quantification of lymphatic tracer clearance and tracer transport to blood inmice. (A) Lymphatic clearance assay of PEGylated tracers in
mouse ear skin. Images are acquired at several time points after injection (left panels) and the loss of normalized fluorescence (NF) intensity exhibits a one-phase exponential decay over
time (right panel). Equations for the lymphatic clearance rate k and the half-life of clearance can be solved as measures of lymphatic function. Modified with permission from [213].
(B) Lymphatic transport to blood assay after intraperitoneal (i.p.) injection of PEGylated 40 kDa fluorescent tracers. After tracer injection, images are acquired at a saphenous vein
region of interest (ROI) with a fluorescence stereomicroscope (example image in left panel) and plotted over time to indicate the transport of the tracer to the systemic blood through
the lymphatic system (right panel). Modified from [175].
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tracers in the draining lymph node after injection into the skin of mice
[100]. As an intradermal administration leads to almost immediate fill-
ing of the lymph node after the injection, modeling of the clearance of
the inert tracer over time as a one-phase exponential decay gives a ru-
dimentary measure of the lymph flow through the node. We have
used this technique in conjunction with ICG liposomes to demonstrate
the blockage of flow through a lymph node that is bearing metastatic
tumor cells and a reduction of lymphatic clearance from chronically-
inflamed skin [100,217]. However, methods quantifying tracer dynam-
ics in draining lymph nodes are highly dependent on the accuracy of
the injection and require anesthesia for the imaging of the lymph
nodes in consistent position over time. As discussed above, such quanti-
fications are also complicated by the fact that many organs have multi-
ple drainage basins with several potential lymph nodes draining the
injected tracers.
To address some of these limitations, an alternative approach of de-
tecting the accumulation of a lymphatic-specific tracer in the systemic
blood has been developed [175,218,219]. As all lymphatic routes even-
tually lead to the bloodstream, this approach simplifies the quantifica-
tion of tracer transport from a specific organ. Previous approaches
required cannulation, however, using PEGylated fluorescent tracers of
40 kDa size, we have found that non-invasive measures of lymphatic
transport to blood can be made with high sensitivity in mice by NIR
monitoring of the signal dynamics in a large superficial blood vessel
[175]. This method allows deeper organs or anatomical cavities to be
assessed, as demonstrated for the peritoneal cavity (Fig. 4B). Using
these measures, we have demonstrated the necessity for tissue motion
for tracers to access the initial lymphatic vessels of the skin. After subcu-
taneous injection into anesthetizedmice, therewas no detectable trans-
port through the lymphatic system to the systemic circulation. If aPlease cite this article as: A.K. Polomska and S.T. Proulx, Imaging techno
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port to the blood in the anesthetized mice was similar to levels seen in
awake animals. This method has also been further utilized to reveal
that inert tracers injected into the CSF of mice appear to drain exclu-
sively through routes leading to lymphatic vessels, instead of directly
to veins as commonly thought [132,220]. These techniques have also re-
vealed that CSF outflow to lymphatics is substantially increased in
awake conditions and is reduced in aged mice. Limitations of this tech-
nique include the need for large amounts of injected tracer and the re-
quirement of the tracer to have a long plasma circulation for sensitive
dynamic assessments in the systemic blood.
5. Emerging imaging techniques for the clinic
In the final section of this review, wewill describe hownew imaging
technology is being translated to the clinic for visualization and quanti-
fication of the lymphatic system. As we have detailed, many pre-clinical
studies have focused on the development and application of novel safe,
stable, bright and highly lymphatic-specific tracers. Despite excellent
performance in animal studies of some of these tracers, very few are
being translated to the clinics, likely due to the low potential of patent
protection, high costs of clinical testing andminimal interest of pharma-
ceutical companies. Thus, most recent clinical efforts have been on the
development of systems that can use existing tracers, such as ICG, or
can provide information in a tracer-free manner, such as ultra high-
frequency ultrasound.
Among new imaging modalities, photoacoustic imaging is a most
promising technique as it allows for real-time imaging of the lymphatic
structures at high depths (~2.5 cm) and excellent spatial resolution
(~160 µm) using safe and well-established optical tracers, such as ICG.
While the low quantum yield of ICG makes it not an ideal tracer forlogy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
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context of photoacoustic imaging, because of an improved conversion of
absorbed light energy to heat. Photoacoustic visualization systems for
clinical applications are not commercially available yet. However, proto-
type devices (such as PAI-05 and AcoustiX) have been used for simulta-
neous imaging of the lymphatic and blood vessels in published clinical
studies [221–223].
Using the PAI-05 system, strikingly sharp images of the lymphatic
and blood vasculature network in a large field of view in the limbs of
healthy volunteers and lymphedema patients have been recently ob-
tained, on which superficial lymphatic vasculature with dermal back-
flow of ICG, as well as the deeper collecting vessels, could be
visualized (Fig. 5A) [223]. On the other hand, the AcoustiX system was
able to visualize the lymphatics along with the blood vessels in real
time in a smaller field of view (50 × 7 mm) up to 2.6 cm below the
skin; however, the overall OA image quality is lower compared to that
obtained using PAI-05 [222]. A disadvantage of both devices lies in
their large size and the fact that the limb has to be immersed in aFig. 5. Emerging clinical imaging techniques. (A) Optoacoustic imaging. Medial side view of the
and in legswith lymphedema (third and fourth images). Images showing both blood and lymph
fine network of dermal lymphatic vessels are observed in the extremity with lymphedema. Re
with ICG-Kolliphor HS15 and hand-held device. Normalized signal disappearance at the m
fluorescence signal was measured using a custom hand-held device without imaging capabili
leg. Lymphatic vessels (yellow arrows), small saphenous vein (blue arrow) and sural nerve (r
reader is referred to the web version of this article.)
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optoacoustic imaging tomography (MSOT) system (MSOT Acuity
Echo) can be operated in a hand-held 3D mode and only ultrasound
gel is necessary for the imaging, which enables performance of this pro-
cedure at the bedside. This prototype system allowing both OA and US
imaging modes is now available for clinical studies, while its predeces-
sor model (MSOT Acuity - without the US imaging capability) has
been recently CE-marked [107]. In a small study with 11 lymphedema
patients, MSOT Acuity Echo was used to visualize lymphatic vessels in
the limbs in regions that were concealed by dermal backflow in ICG
lymphography. The capability of real-time 3D simultaneous imaging of
blood and lymphatic vessels with good spatiotemporal resolution
makes MSOT especially valuable for choosing the appropriate sites for
the LVA [224]. Photoacoustic imaging has also been tested in humans
in the context of SLNs and detectingmetastatic burden inmelanoma pa-
tients [225,226]. In sum, further development is still required for clinical
instrumentation, imaging probes and protocols for photoacoustic imag-
ing in the context of the lymphatic system.However, the recent increasephotoacoustic lymphangiography of the healthy lower leg (first two images from the left)
atic vessels (first and third) and only lymphatics (second and fourth). Dermal backflowand
printed with permission [223]. (B) Quantitative assessment of lymphatic function in pigs
assaged and not massaged injection sites and signal quantification with the AUC. The
ty [91]. (C) Ultra high frequency ultrasound. Imaging in the posterior aspect of the lower
ed arrow) [227]. (For interpretation of the references to colour in this figure legend, the
logy of the lymphatic system, Adv. Drug Deliv. Rev., https://doi.org/
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nique is likely to be embraced for routine application in patients.
In a recent study from our group,we investigated in pigs a clinically-
relevant technique for quantification of the lymphatic clearance based
on measuring the disappearance of the tracer at the injection site after
intradermal administration. In this method, ICG was encapsulated
in micelles of polyoxyl 15 hydroxystearate (Kolliphor HS15) that
prevented self-quenching, increased the quantum yield and improved
the stability of the dye in solution. The ICG-Kolliphor HS15 solution
was injected using MicronJet600™ microneedles (Nanopass Ltd) that
allowed for precise and pain-free intradermal administration. We mea-
sured thefluorescence signal over timeusing a custom-made hand-held
device that allows simple NIR-fluorescence signal quantification with-
out the need for imaging capability. In particular, in this study, we dem-
onstrated differences in lymphatic clearance in different parts of the pig
abdomen and upon application of manual stimulation (massage)
(Fig. 5B). The clearance was quantified by calculating the area under
the normalized clearance curves (AUCs) [91]. We are currently investi-
gating the feasibility of this technique to quantify lymphatic clearance in
patients with established unilateral extremity lymphedema.
Ultra-high frequency ultrasound imaging is characterized by the im-
proved resolution and quality of the image compared to conventional
ultrasound. Recently, ultra-high frequency ultrasound, operating at
70 kHZwas used to visualize subcutaneous lymphatic vessels of a diam-
eter smaller than 30 μm, as well as of the lymphatic flow and lymphatic
valves in some vessels (Fig. 5C) [227,228]. On the US images, the lym-
phatic vessels can be identified as intermittent homogenous,
hypoechoic and specular misshapen structures [227–232]. In contrast
to blood vessels, lymphatic vessels do not collapse upon applying pres-
sure with the transducer head [227,232,233]. US can be used for visual-
ization of the lymphatic vessels for LVA surgery. Themajor advantage of
using US over ICG imaging before LVA as well as intraoperatively is the
possibility to visualize the lymphatic and blood vessels in a region
where they are concealed by a dermal backflow pattern of ICG
[227,228].
In conclusion, the lymphatic imagingmodalities described in this re-
view can allow for qualitative visualization and quantitative assessment
of the lymphatic system. While most of the techniques require intersti-
tial injection of the tracer to provide contrast between the tissue and
lymphatic structures, some emerging techniques are allowing visualiza-
tion of lymphatics in a tracer-freemanner. In clinical settings, lymphatic
imaging is predominantly being performed with conventional tracers
that have been approved since several years or even decades. Further
development is focused mainly on improvement of measurement pro-
tocols and defining new quantitative parameters. Although the tech-
niques and tracers for visualization of the lymphatic system are less
developed than for the other anatomical structures, with the recent in-
creased attention to lymphatic system function and development, we
anticipate continued improvement in lymphatic imaging technology
in the coming years.
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